SEPSF (ASEP Medical Holdings) EBIT per Share : $-0.06 (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings EBIT per Share?

ASEP Medical Holdings's EBIT per Share for the three months ended in Sep. 2024 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for ASEP Medical Holdings's EBIT per Share or its related term are showing as below:

SEPSF's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

ASEP Medical Holdings's EBIT for the three months ended in Sep. 2024 was $-0.71 Mil.

ASEP Medical Holdings EBIT per Share Historical Data

The historical data trend for ASEP Medical Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASEP Medical Holdings EBIT per Share Chart

ASEP Medical Holdings Annual Data

Trend

Dec21

Dec22

Dec23

EBIT per Share

-0.03

-0.08

-0.11

ASEP Medical Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial										-0.02	-0.03	-0.01	-0.01	-0.01

ASEP Medical Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

ASEP Medical Holdings's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.029	/	62.235
=	-0.11

ASEP Medical Holdings's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.711	/	76.444
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

ASEP Medical Holdings (OTCPK:SEPSF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

ASEP Medical Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of ASEP Medical Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ASEP Medical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

JJ8:Germany ASEP:Canada

Address

730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7

Website

https://www.asepmedical.com

ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.